CSPC Pharma teases big bucks deals after earnings miss
The Chinese drug giant revealed it was in talks with three parties to license its products for up to $5 billion in potential fees, a day after it delivered lackluster…
Earnings blow for CSPC Pharma as the state drives a hard bargain
The generic drugs giant has warned of a 26% slide in annual profits after China’s national healthcare system imposed big price cuts on qualifying medicines Key Takeaways: CSPC Pharma…
AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt
Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM…
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- RNA drug developer Ribo Life targets fresh funding channel
- Will Trump’s drug order put the brakes on China’s overseas pharma drive?
